MVIR:STO
Medivir AB
SEK 1.72
arrow_upward
+1.42%(+0.024) 1D
7-р сарын 24, 17:29:33 (GMT+2) · SEK
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK 1.70
High
SEK 1.73
Low
SEK 1.68
Mkt. cap
1.06 тэрбум
Avg. vol.
1.82 сая
Volume
701.11 мян
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.54
Shares outstanding
617.94 сая
No. of employees
7
Open
SEK 1.70
High
SEK 1.73
Low
SEK 1.68
Mkt. cap
1.06 тэрбум
Avg. vol.
1.82 сая
Volume
701.11 мян
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.54
Shares outstanding
617.94 сая
No. of employees
7
News stories
From sources across the web
MarketBeat
·
2 минутын өмнө
Neogen Corporation (NASDAQ:NEOG) Receives Average Rating of "Hold" from Brokerages
Crypto News
·
21 минутын өмнө
LMAX eyes $5B Nasdaq IPO as sale talks gather pace
MarketBeat
·
4 минутын өмнө
SEI Investments Company (NASDAQ:SEIC) Receives Average Recommendation of "Buy" from Brokerages
Investor's Business Daily
·
5 цагийн өмнө
Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
AI content may include mistakes. Learn more